Filter By Category
Archives
Share on -
ANSUVIMAB
Generic Name: ANSUVIMAB
ABSTRACT -
Ansuvimab is a monoclonal antibody against the glycoprotein of Zaire ebolavirus.
It is marketed as EBANGA and is used for treatment of infection caused by Orthoebolavirus zairense in adult and pediatric patients.
The product is a biologic antibody and is represented by a protein/antibody structure.
DOSAGE -
- Dosage should be determined only by a qualified healthcare professional.
- Recommended dosage for adults and pediatric patients is 50 mg/kg as a single intravenous infusion.
- The infusion is administered over approximately 60 minutes after reconstitution and dilution.
- Treatment must be provided in a setting capable of Ebola isolation, supportive care, and monitoring.
SIDE EFFECTS–
- Possible side effects may include:
- Fever
- Tachycardia
- Diarrhea
- Vomiting
- Hypotension or chills during infusion
- Infusion-related reaction
- Hypersensitivity
- Clinical complications of Ebola virus disease
ALLRGIC REACTIONS–
- Hypersensitivity to the active biologic or formulation excipients is possible.
- Symptoms may include rash, urticaria, pruritus, facial swelling, bronchospasm, fever, chills, hypotension, or anaphylaxis.
- Patients with a suspected allergic reaction should stop treatment and seek urgent medical attention.
DRUG INTERACTIONS–
- Avoid concurrent live-virus vaccination for Ebola when antibody therapy may reduce vaccine effectiveness.
- Review experimental antivirals or immune therapies for additive infusion or immune effects.
- Supportive medicines should be coordinated by infectious-disease specialists.
PREAUTIONS–
- Use infection-control precautions for Ebola virus disease.
- Monitor vital signs during and after infusion.
- Correct dehydration, electrolyte abnormalities, and organ dysfunction as clinically indicated.
- Consider circulating viral susceptibility information when selecting therapy.
WARNINGS –
- Ebola virus disease is life-threatening and requires specialized care.
- Infusion reactions and hypersensitivity can occur.
- Delay in supportive care can worsen outcomes.
Share on -
. Developed by